The addition of vascular endothelial growth factor (VEGF) inhibitors to EGFR-TKIs in the first-line treatment of patients with EGFR-mutant NSCLC has been investigated; differential results have been revealed regarding the survival benefit between the combination of erlotinib plus bevacizumab [110] and osimertinib plus bevacizumab [111], a phenomenon that may reflect the tumor cell heterogeneity caused by different EGFR-TKIs. This evidence concerns the gene EGFR and neoplasm.